CASI Pharmaceuticals (CASIF) Accumulated Expenses (2022 - 2025)

CASI Pharmaceuticals has reported Accumulated Expenses for 4 years, with the latest figure at $20.0 million in Q3 2025.

• For the quarter ending Q3 2025, Accumulated Expenses changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Sep 2025 stood at $20.0 million (changed N/A YoY), and the FY2024 full-year result was $15.3 million, down 99.88% from the prior year.
• Accumulated Expenses for Q3 2025 stood at $20.0 million, up from $18.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $14.0 billion in Q1 2025, with the low at $8.0 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $5.0 billion across 4 years, with a median of $20.0 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses slumped 99.88% — and 2025, when it jumped 176083.9%.
• CASI Pharmaceuticals' Accumulated Expenses stood at $11.8 million in 2022, then surged by 103894.58% to $12.3 billion in 2023, then tumbled by 99.88% to $15.3 million in 2024, then surged by 30.38% to $20.0 million in 2025.
• The last three Accumulated Expenses figures came in at $20.0 million (Q3 2025), $18.2 million (Q2 2025), and $14.0 billion (Q1 2025), per Business Quant data.